November 21, 2016 - By Ellis Scott · 0 Comments
The stock of Volitionrx Limited (NYSEMKT:VNRX) registered an increase of 64.1% in short interest. VNRX’s total short interest was 160,000 shares in November as published by FINRA. Its up 64.1% from 97,500 shares, reported previously. With 94,400 shares average volume, it will take short sellers 2 days to cover their VNRX’s short positions. The short interest to Volitionrx Limited’s float is 0.96%. The stock increased 9.27% or $0.38 on November 18, hitting $4.48. VolitionRX Ltd (NYSEMKT:VNRX) has risen 19.79% since April 19, 2016 and is uptrending. It has outperformed by 15.93% the S&P500.
VolitionRx Limited is a clinical-stage life sciences company. The company has a market cap of $127.73 million. The Firm is focused on developing blood diagnostic tests for detecting and diagnosing cancer and other diseases. It currently has negative earnings. The Firm has developed approximately 30 blood assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.
Insitutional Activity: The institutional sentiment decreased to 1.8 in Q2 2016. Its down 1.70, from 3.5 in 2016Q1. The ratio turned negative, as 1 funds sold all VolitionRX Ltd shares owned while 1 reduced positions. 2 funds bought stakes while 5 increased positions. They now own 6.13 million shares or 0.84% more from 6.08 million shares in 2016Q1.
Blackrock Ltd Limited Liability Company has 1,424 shares for 0% of their US portfolio. Asset Management holds 0.01% of its portfolio in VolitionRX Ltd (NYSEMKT:VNRX) for 12,000 shares. Moreover, Knoll Mngmt Ltd Partnership has 0.47% invested in VolitionRX Ltd (NYSEMKT:VNRX) for 461,538 shares. Savings Bank Of America De holds 1 shares or 0% of its portfolio. Geode Cap Mgmt Ltd Liability holds 0% of its portfolio in VolitionRX Ltd (NYSEMKT:VNRX) for 63,662 shares. Blackrock Fund Advisors last reported 2,349 shares in the company. Bank Of New York Mellon Corp last reported 0% of its portfolio in the stock. Morgan Stanley has 51,900 shares for 0% of their US portfolio. Tower Rech Capital (Trc) has 659 shares for 0% of their US portfolio. Goldman Sachs Grp Inc accumulated 19,388 shares or 0% of the stock. Blackrock Inc owns 1,000 shares or 0% of their US portfolio. Garrison Bradford & Assocs has 0.05% invested in the company for 15,500 shares. Southpoint Capital Advsrs L P accumulated 800,000 shares or 0.13% of the stock. Creative Planning accumulated 3,200 shares or 0% of the stock. Lagoda Mngmt L P holds 1.62M shares or 1.9% of its portfolio.
Insider Transactions: Since October 5, 2016, the stock had 1 insider purchase, and 0 selling transactions for $50,000 net activity. 10,000 shares with value of $50,000 were bought by KRATOCHVIL DAVID MATTHEW on Wednesday, October 5.
VolitionRx Limited, incorporated on September 24, 1998, is a clinical-stage life sciences company. The Firm is focused on developing blood diagnostic tests for detecting and diagnosing cancer and other diseases. The Firm has developed approximately 30 blood assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company’s Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Firm is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company’s NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T.
More notable recent VolitionRX Ltd (NYSEMKT:VNRX) news were published by: Prnewswire.com which released: “VolitionRx Limited to Present at the Canaccord Genuity Medical Technologies …” on November 11, 2016, also Quotes.Wsj.com with their article: “VolitionRX Ltd. VNRX (US: NYSE MKT)” published on May 24, 2014, Marketwatch.com published: “VolitionRX Ltd. NYSE MKT: VNRX” on October 31, 2011. More interesting news about VolitionRX Ltd (NYSEMKT:VNRX) were released by: Prnewswire.com and their article: “VolitionRx Limited Schedules Third Quarter 2016 Earnings Conference Call and …” published on November 04, 2016 as well as Prnewswire.com‘s news article titled: “VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriter” with publication date: October 21, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott